Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)?

The Journal of Clinical Pharmacology

Volumn 32, Issue 6, 1992, Pages 539-545

  Koenig, Wolfgang ^a   Hehr, Reinhard ^a   Ditschuneit, Herwig H ^a   Kuhn, Klaus ^a   Ernst, Edzard ^b,c   Rosenthal, Julian ^a   Hombach, Vinzenz ^a  

^a Section of Pharmacotherapy ^*

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ADULT; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL ARTICLE; ERYTHROCYTE AGGREGATION; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; MALE; ORAL DRUG ADMINISTRATION; PLASMA VISCOSITY;

BEZAFIBRATE; BLOOD VISCOSITY; COMPARATIVE STUDY; DELAYED-ACTION PREPARATIONS; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; LIPIDS; LIPOPROTEINS; LOVASTATIN; MALE; MIDDLE AGE; RHEOLOGY; SINGLE-BLIND METHOD;

EID: 0026695499     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/009127009203200609     Document Type: Article

References (44)

1. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
2. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. II. Relations of the variables to “risk factors” for myocardial infarction
3. Fibrinogen as a risk factor for stroke and myocardial infarction
4. Fibrinogen and risk of cardiovascular disease. The Framingham Study
5. Hemorheological parameters in hyperlipoproteinemia: Results from the MONICA‐project Augsburg FRG
6. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinemia
7. Increased plasma fibrinogen and platelet‐aggregates in type II hyperlipoproteinemia
8. Association between dietary fat intake and plasma factor VII coagulant activity: A predictor of cardiovascular mortality
9. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity
10. Effect of treatment of hyperlipidaemia on haemostatic variables
11. Studies of plasma viscosity in primary hyperlipoproteinemia
12. Effects of lipoproteins on plasma viscosity
13. Increased plasma apolipoprotein B levels and blood hyperviscosity in non‐insulin‐dependent diabetic patients: Role in the occurrence of arterial hypertension
14. Hämorheologische Veränderungen bei Hyperlipoproteinämien vom Typ IIa, IIb und IV
15. Standardization of blood specimen collection procedure for reference values
16. Estimation of plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge
17. Immunochemical quantitation of antigen by single radial immunodiffusion
18. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
19. Long term administration of lovastatin in the treatment of hypercholesterolemia
20. HMG‐CoA reductase inhibitors for treatment of hypercholesterolemia
21. Finnish Lovastatin Study Group: Comparison between lovastatin and gem‐fibrozil in the treatment of primary hypercholesterolemia: The Finnish Multicenter Study
22. Hemorheological profile in patients with familial hypercholesterolemia: Effect of lipid lowering therapy
23. Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels
24. Rheological effects of lipid lowering therapy with lovastatin in patients with familial hypercholesterolemia
25. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidemia and atherosclerosis
26. Lipoprotein(a): A genetically determined lipoprotein containing a glycoprotein of the plasminogen family
27. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia
28. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG‐CoA reductase inhibitor
29. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis
30. Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B
31. Binding of plasminogen to culture human endothelial cells
32. A potential basis for the thrombotic risks associated with lipoprotein (a)
33. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
34. Effect of lovastatin on platelet lipid composition, membrane fluidity and aggregation in patients with hypercholesterolemia (abstr.)
35. Blood rheology under antilipemic therapy in hyperlipoproteinemias
36. Einfluß von Fenofibrat auf die Blutrheologie
37. Blood rheology changes during bezafibrate treatment
38. Effect of short‐term treatment with bezafibrate on plasma fibrinogen, fibrinopep‐tide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients
39. Hemorheological activity of gemfibrozil in primary hyperlipidemias
40. LDL‐cholesterol, an underestimated determinant of plasma viscosity
41. Highly significant negative correlations between erythrocyte aggregation value and serum concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease
42. Interaction of lipoprotein(a) with fibronectin and its potential role in atherogenesis
43. Is the atherogenecity of Lp(a) caused by its reactivity with proteoglycans
44. Regression of coronary artery disease as a result of intensive lipid‐lowering therapy in men with high levels of apolipoprotein B